TCTMD

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...
Healio

Low-dose colchicine lowers incidence of knee and hip replacements, study finds

Please provide your email address to receive an email when new articles are posted on . Benefits of low-dose colchicine were consistent in men over a median follow-up period of 28.6 months. Due to low ...
Healio

Review: Colchicine helpful in stable CAD, but long-term safety unknown

Please provide your email address to receive an email when new articles are posted on . In the research summary written on behalf of the LoDoCo2 Steering Committee, researchers said the self-assembly ...
Medscape

Colchicine a New Tool for Ischemic Stroke, CVD Event Recurrence?

BASEL, SWITZERLAND — The anti-inflammatory agent colchicine failed to show significant benefit in the treatment of patients with non-cardioembolic ischemic stroke in the primary analysis of the ...
TCTMD

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Low-dose colchicine not only lowers the risk of ischemic CV events post-MI, it also can do so cost-effectively, according to the latest numbers from COLCOT. This is true from the perspective of the ...